Filing Details

Accession Number:
0001140361-17-035546
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-14 17:06:06
Reporting Period:
2017-09-12
Accepted Time:
2017-09-14 17:06:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012477 Avadel Pharmaceuticals Plc AVDL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1207106 R Craig Stapleton Block 10-1, Blanchardstown
Corporate Park, Ballycoolin
Dublin L2 15
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Adss Acquisiton 2017-09-12 20,000 $9.52 110,000 No 4 P Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Spouse
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Adss 507,678 Direct
Adss 16,200 Indirect By Trust
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Adss Warrants (right to buy) $14.54 2015-06-24 2018-06-24 100,000 100,000 Direct
Adss Warrants (right to buy) $21.67 2016-06-26 2019-06-26 117,449 117,449 Direct
Adss Warrants (right to buy) $13.59 2017-08-10 2020-08-10 117,449 117,449 Direct
Adss Stock Option (right to buy) $10.51 2018-06-28 2022-06-28 30,000 30,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2018-06-24 100,000 100,000 Direct
2019-06-26 117,449 117,449 Direct
2020-08-10 117,449 117,449 Direct
2022-06-28 30,000 30,000 Direct
Footnotes
  1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.14 to $9.84, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
  3. The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities.
  4. Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
  5. Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS.
  6. Warrants were granted 08/10/2016 but are not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants will become exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vest on 08/10/2017.
  7. Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date.